OBJECTIVE: This study evaluated Medicaid's prior-authorization policies restricting the prescribing of antidepressant medications for children. METHODS: Medicaid program prior-authorization policies for antidepressant medications were obtained for all available states. All criteria needed for authorization were recorded, with a focus on policies that applied specifically to children. RESULTS: Data from 49 states and the District of Columbia revealed that 30 states (60%) required prior authorization for antidepressants, of which eight (27%) made specific provisions for children. These provisions varied across states. In most states fluoxetine could be prescribed for children with minimal restrictions, and two states had prior-authorization policies that strongly encouraged pediatric patients to use fluoxetine. State policies regarding other selective serotonin reuptake inhibitors varied widely. CONCLUSIONS: Although relatively few states included provisions for children in prior-authorization requirements for antidepressants, in states that did, the policies implemented varied widely. These findings raise important questions about the rational development of prescription drug reimbursement policy.
OBJECTIVE: This study evaluated Medicaid's prior-authorization policies restricting the prescribing of antidepressant medications for children. METHODS: Medicaid program prior-authorization policies for antidepressant medications were obtained for all available states. All criteria needed for authorization were recorded, with a focus on policies that applied specifically to children. RESULTS: Data from 49 states and the District of Columbia revealed that 30 states (60%) required prior authorization for antidepressants, of which eight (27%) made specific provisions for children. These provisions varied across states. In most states fluoxetine could be prescribed for children with minimal restrictions, and two states had prior-authorization policies that strongly encouraged pediatric patients to use fluoxetine. State policies regarding other selective serotonin reuptake inhibitors varied widely. CONCLUSIONS: Although relatively few states included provisions for children in prior-authorization requirements for antidepressants, in states that did, the policies implemented varied widely. These findings raise important questions about the rational development of prescription drug reimbursement policy.
Authors: Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom Journal: J Child Adolesc Psychopharmacol Date: 2014-08-21 Impact factor: 2.576
Authors: Michael A Fischer; Jennifer M Polinski; Amber D Servi; Jessica Agnew-Blais; Liljana Kaci; Daniel H Solomon Journal: Arthritis Rheum Date: 2008-11-15